Robitussin DM is a popular over-the-counter medication used to treat coughs and colds. It contains two active ingredients: dextromethorphan, an antitussive that helps suppress coughs, and guaifenesin, an expectorant that helps thin and loosen mucus in the lungs. Robitussin DM is available in a variety of forms, including liquid, capsule, and tablet. While it is generally safe and effective when taken as directed, it is important to understand the proper dosage and potential side effects. This guide will provide an overview of Robitussin DM, including information about its uses, dosage, and potential side effects.
Robitussin DM is used to treat coughs and colds. The dextromethorphan in Robitussin DM helps suppress coughs, while the guaifenesin helps thin and loosen mucus in the lungs. Robitussin DM is available in a variety of forms, including liquid, capsule, and tablet. It is generally safe and effective when taken as directed.
Robitussin DM should be taken as directed on the package or as directed by a doctor. The recommended dose for adults and children over 12 years of age is two teaspoons (10 mL) every 4 to 6 hours, not to exceed 12 teaspoons (60 mL) in 24 hours. For children 6 to 12 years of age, the recommended dose is one teaspoon (5 mL) every 4 to 6 hours, not to exceed 6 teaspoons (30 mL) in 24 hours. For children under 6 years of age, Robitussin DM should not be used without consulting a doctor.
Robitussin DM is generally safe and effective when taken as directed. However, like all medications, it can cause side effects. Common side effects include nausea, vomiting, dizziness, drowsiness, and dry mouth. If these side effects persist or worsen, contact a doctor. Serious side effects are rare but can include difficulty breathing, chest tightness, and irregular heartbeat. If these side effects occur, seek medical help immediately.
Robitussin DM should not be taken by anyone who is allergic to any of its ingredients. It should also not be taken by anyone who has high blood pressure, heart disease, glaucoma, or an overactive thyroid. It should also not be taken by anyone who has taken a monoamine oxidase inhibitor (MAOI) in the past 14 days. Robitussin DM should not be taken by anyone who is pregnant or breastfeeding without consulting a doctor.
Robitussin DM can interact with certain medications, including MAOIs, sedatives, antidepressants, and other cough and cold medications. Before taking Robitussin DM, it is important to tell a doctor or pharmacist about all medications that are currently being taken.
Robitussin DM is a popular over-the-counter medication used to treat coughs and colds. It contains two active ingredients: dextromethorphan, an antitussive that helps suppress coughs, and guaifenesin, an expectorant that helps thin and loosen mucus in the lungs. Robitussin DM is generally safe and effective when taken as directed, but it is important to understand the proper dosage and potential side effects. This guide has provided an overview of Robitussin DM, including information about its uses, dosage, and potential side effects.
1.
Remote monitoring can improve recovery from cancer surgery
2.
Intractable cancers may respond better to treatment when using new radiation and high-performance computing.
3.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
4.
Conditional EU Nod for Weekly Pill in Pediatric Glioma
5.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
1.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
2.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
5.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation